about
Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical reviewHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trialMetagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteriaDistance management of inflammatory bowel disease: systematic review and meta-analysisThe bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients.Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease.Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding.The epidemiology of inflammatory bowel disease in Canada: a population-based study.Patients with inflammatory bowel disease exhibit dysregulated responses to microbial DNAVedolizumab as induction and maintenance therapy for Crohn's disease.Epithelial gaps in a rodent model of inflammatory bowel disease: a quantitative validation studyIncreased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel diseaseBreaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos).Prospective Study of the Quality of Colonoscopies Performed by Primary Care Physicians: The Alberta Primary Care Endoscopy (APC-Endo) Study.Don't Forget the Doctor: Gastroenterologists' Preferences on the Development of mHealth Tools for Inflammatory Bowel DiseaseDrug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.Probiotics and the management of inflammatory bowel disease.Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy.Is it time to re-classify Crohn's disease?Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples.Probiotics and prebiotics in gastrointestinal disorders.TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development.Postoperative Crohn's disease.The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics.Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.Probiotics in the treatment of inflammatory bowel disease.A 29-year-old woman with Crohn disease considering pregnancy.The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease.Metabolomic profiles are gender, disease and time specific in the interleukin-10 gene-deficient mouse model of inflammatory bowel disease.Molecular patterns in human ulcerative colitis and correlation with response to infliximabAdalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.Disease manifestations of Helicobacter pylori infection in Arctic Canada: using epidemiology to address community concerns.Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis.Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.A machine-learned predictor of colonic polyps based on urinary metabolomics.
P50
Q26823927-6C4C6E4F-1447-48FC-949C-F3994DA30F8EQ28296771-2B15CD2C-6868-462F-9956-373F17A85123Q28646298-6D0FC02F-4331-4E05-B0AB-BAA2D06E308DQ30486789-CB6A53DF-C4E0-458D-B0B9-F58C6756AD6CQ33250647-18C0D962-3205-42AE-B7E5-FE860A63B991Q33732599-D457B577-11DC-4358-9871-FB547BA63C86Q33792368-F42613CE-0E8F-4E11-8FAB-16B4070DE09FQ33997864-70137AFE-D91B-4421-89C1-DCC180743CCEQ34287642-B1FCE8D3-A802-4E10-B572-0A68D42F3B4AQ34365574-A429C5B3-39E4-4945-9C0C-BBD9A1C755CCQ34511748-C36ED468-F222-4FFB-A3F9-32F51CAD3A05Q34511806-761BB4E6-679C-47D1-BCB6-42B6BDDB1438Q34565768-52A84C40-91AB-4461-921B-5E726429ABBAQ34796336-0DA23A72-E47A-467A-BA77-C77E07635059Q35056003-03A4E9C5-A2B1-4895-9460-B241EFD458B8Q35624602-006180D1-49E7-4956-8578-F6417C7E23C3Q35655989-066BC940-3520-4790-966D-CD16F51B4131Q35854517-F8176C5E-2A7B-4CD6-BAEB-7959EB187A50Q35959598-E1E3E178-5CCE-4F19-A1AD-036B7F00823AQ35978793-0E8F29F8-D05C-4801-9F3E-8E6E9D4D4021Q35995244-99355329-272F-4F33-A45F-D0F485A0D00BQ36036491-2FD10D59-87DA-4931-A407-B384BEC7E966Q36085572-77609495-FF24-4A0D-BFA9-00C17AB5AD4AQ36207261-F34646FC-ACE6-462F-9BBC-6B43D9FF488CQ36220431-BDDDD0E5-E5A7-4E99-A823-5ED8AE76F12DQ36285782-16A1AA4C-1BBC-4B09-A3FE-F8E14D2D1433Q36428382-CBDBA50F-AA49-4607-8209-41235CFA7B10Q36457614-367A0353-A6B0-4ACF-BC99-A94A2DCD3A2DQ36520699-02FE2E08-06F0-48F8-86B5-96B996EBCD05Q36653913-196D5763-9FFF-4F3B-AB0C-90DF0F5D0D6DQ36997228-FDEF1D03-2C34-4F1D-9F04-9A9EFFCE64EAQ37175815-BD9520FD-6B0A-4041-A67A-0DDE01D629BFQ37240622-1BD68CA3-6D59-4390-BB5E-EE9CA2891892Q37342575-248B7964-3844-48AB-B6A8-6B2F4929CE82Q37516556-D8F24706-FC0C-4BF3-8DF6-76D39FB733BDQ37800674-F48010FB-C64B-4153-B75E-2EA93F3F6B10Q37992243-0CBE8475-ED18-41CF-8D22-652D81B0E617Q38121115-B3D4470B-EB95-4147-83F6-41FD00E8AF02Q38184706-A8405D9F-A9A9-491D-8298-83339F82A3BFQ39301057-55E6FA60-45B5-4358-A169-5BDEA41D2320
P50
description
Canadees onderzoeker (1955-2018)
@nl
kanadischer Arzt
@de
médicu canadianu (1955–2018)
@ast
researcher ORCID ID = 0000-0002-7382-0080
@en
name
Richard N. Fedorak
@ast
Richard N. Fedorak
@ca
Richard N. Fedorak
@en
Richard N. Fedorak
@es
Richard N. Fedorak
@fr
Richard N. Fedorak
@ga
Richard N. Fedorak
@nl
Richard N. Fedorak
@sl
Richard N. Fedorak
@sq
type
label
Richard N. Fedorak
@ast
Richard N. Fedorak
@ca
Richard N. Fedorak
@en
Richard N. Fedorak
@es
Richard N. Fedorak
@fr
Richard N. Fedorak
@ga
Richard N. Fedorak
@nl
Richard N. Fedorak
@sl
Richard N. Fedorak
@sq
altLabel
Richard Fedorak
@en
prefLabel
Richard N. Fedorak
@ast
Richard N. Fedorak
@ca
Richard N. Fedorak
@en
Richard N. Fedorak
@es
Richard N. Fedorak
@fr
Richard N. Fedorak
@ga
Richard N. Fedorak
@nl
Richard N. Fedorak
@sl
Richard N. Fedorak
@sq
P463
P101
P106
P1153
7005513192
P19
P1960
NFr3YykAAAAJ
P2038
Richard_Fedorak
P21
P213
0000 0001 3777 8535
P27
P2941
richard-neil-fedorak
P31
P463
P496
0000-0002-7382-0080
P569
1955-05-28T00:00:00Z
P570
2018-11-08T00:00:00Z